AU2008266515B2 - Pyrrole derivatives as P2Y12 antagonists - Google Patents

Pyrrole derivatives as P2Y12 antagonists Download PDF

Info

Publication number
AU2008266515B2
AU2008266515B2 AU2008266515A AU2008266515A AU2008266515B2 AU 2008266515 B2 AU2008266515 B2 AU 2008266515B2 AU 2008266515 A AU2008266515 A AU 2008266515A AU 2008266515 A AU2008266515 A AU 2008266515A AU 2008266515 B2 AU2008266515 B2 AU 2008266515B2
Authority
AU
Australia
Prior art keywords
phenyl
alkylene
alkyl
methyl
pyrrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008266515A
Other languages
English (en)
Other versions
AU2008266515A1 (en
Inventor
Joerg Czech
Werngard Czechtizky
Melitta Just
Otmar Klingler
Tilo Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU2008266515A1 publication Critical patent/AU2008266515A1/en
Assigned to SANOFI reassignment SANOFI Amend patent request/document other than specification (104) Assignors: SANOFI-AVENTIS
Application granted granted Critical
Publication of AU2008266515B2 publication Critical patent/AU2008266515B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008266515A 2007-06-18 2008-06-04 Pyrrole derivatives as P2Y12 antagonists Ceased AU2008266515B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290755.3 2007-06-18
EP07290755 2007-06-18
PCT/EP2008/004459 WO2008155022A1 (en) 2007-06-18 2008-06-04 Pyrrole derivatives as p2y12 antagonists

Publications (2)

Publication Number Publication Date
AU2008266515A1 AU2008266515A1 (en) 2008-12-24
AU2008266515B2 true AU2008266515B2 (en) 2014-05-01

Family

ID=39092503

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008266515A Ceased AU2008266515B2 (en) 2007-06-18 2008-06-04 Pyrrole derivatives as P2Y12 antagonists

Country Status (12)

Country Link
US (1) US7910576B2 (enExample)
EP (1) EP2167487B1 (enExample)
JP (1) JP5371969B2 (enExample)
KR (1) KR20100020478A (enExample)
CN (1) CN101679358B (enExample)
AU (1) AU2008266515B2 (enExample)
BR (1) BRPI0812912A2 (enExample)
CA (1) CA2690243A1 (enExample)
IL (1) IL202758A (enExample)
MX (1) MX2009013431A (enExample)
MY (1) MY148901A (enExample)
WO (1) WO2008155022A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2102195A1 (en) 2006-10-20 2009-09-23 Novartis AG Crystal modifications -3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl]-pyrrole-2, 5-d ione
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
IL286902B2 (en) 2019-04-03 2025-03-01 Aligos Therapeutics Inc Pyrrole compounds
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3458515A (en) * 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US20030119817A1 (en) * 2001-07-16 2003-06-26 Anita Mehta Oxazolidinone derivatives as potential antimicrobials
WO2005073203A1 (en) * 2004-01-16 2005-08-11 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF
CN1778801A (zh) * 2004-11-22 2006-05-31 中国农业科学院兰州畜牧与兽药研究所 喹诺酮7－((4－((z)－2－(2－氨基－4－噻唑基)－2－甲氧亚胺乙酰基)－1－哌嗪基)化合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
CN1747732A (zh) 2002-12-11 2006-03-15 舍林股份公司 作为血小板腺苷二磷酸受体拮抗剂的2－氨基羰基喹啉化合物
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
WO2006073361A1 (en) * 2005-01-06 2006-07-13 Astrazeneca Ab Novel pyridine compounds
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
EP1896483A2 (en) * 2005-03-28 2008-03-12 Pharmacia & Upjohn Company LLC 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2627719C (en) * 2005-11-03 2016-07-12 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
WO2007103456A2 (en) * 2006-03-06 2007-09-13 Trimeris, Inc. Piperazine and piperidine biaryl derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3458515A (en) * 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US20030119817A1 (en) * 2001-07-16 2003-06-26 Anita Mehta Oxazolidinone derivatives as potential antimicrobials
WO2005073203A1 (en) * 2004-01-16 2005-08-11 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF
CN1778801A (zh) * 2004-11-22 2006-05-31 中国农业科学院兰州畜牧与兽药研究所 喹诺酮7－((4－((z)－2－(2－氨基－4－噻唑基)－2－甲氧亚胺乙酰基)－1－哌嗪基)化合物及其制备方法

Also Published As

Publication number Publication date
MY148901A (en) 2013-06-14
JP5371969B2 (ja) 2013-12-18
IL202758A (en) 2013-09-30
US7910576B2 (en) 2011-03-22
EP2167487A1 (en) 2010-03-31
CN101679358B (zh) 2013-10-30
AU2008266515A1 (en) 2008-12-24
US20100226918A1 (en) 2010-09-09
IL202758A0 (en) 2010-06-30
JP2010530380A (ja) 2010-09-09
MX2009013431A (es) 2010-01-15
EP2167487B1 (en) 2015-02-18
HK1142593A1 (en) 2010-12-10
BRPI0812912A2 (pt) 2014-12-09
CN101679358A (zh) 2010-03-24
KR20100020478A (ko) 2010-02-22
WO2008155022A1 (en) 2008-12-24
CA2690243A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
EP2238127B1 (en) Pyrazole-carboxamide derivatives as p2y12 antagonists
US8426420B2 (en) Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists
JP4861306B2 (ja) Ｘａ因子阻害剤としてのピロール誘導体
KR20060136457A (ko) 인자 Ｘａ 억제제로서의 피롤-유도체
MXPA05012346A (es) Derivados de indazol como inhibidores del factor xa.
MXPA05006200A (es) Derivados de pirazol como inhibidores del factor xa.
JP4939401B2 (ja) ＴＡＦＩａ阻害剤として用いるイミダゾール誘導体
US7910576B2 (en) Pyrrole derivatives as P2Y12 antagonists
HUP0200021A2 (hu) 4-(Heterociklikus szulfonamido)-5-metoxi-6-(2-metoxi-fenoxi)-2-fenil- vagy -piridil-pirimidinek, mint endothelin receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
KR20090096742A (ko) 피리딘 화합물 및 ｐ２ｙ１２ 길항제로서의 그 용도
JP4608495B2 (ja) 第Ｘａ因子阻害剤としてのトリアゾール誘導体
AU2003285336B2 (en) Imidazole-derivatives as factor Xa inhibitors
RU2346944C2 (ru) ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
JP5422569B2 (ja) 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類
HK1142593B (en) Pyrrole derivatives as p2y12 antagonists
KR101373533B1 (ko) 인자 Ｘａ 억제제로서의 헤테로아릴-카복실산(설파모일 알킬)아미드 유도체
MXPA06008712A (en) PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired